Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Abstract

Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer. PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolizumab. (Funded by Merck; KEYNOTE-001 ClinicalTrials.gov number, NCT01295827.).

Keywords

Affiliated Institutions

• Vanderbilt-Ingram Cancer Center
• Vall d'Hebron Institute of Oncology
• University of California, Los Angeles US
• Seoul National University KR
• South Texas Accelerated Research Therapeutics US
• Yale University US
• Université Paris-Sud FR
• Institut Gustave Roussy FR
• Angeles Clinic and Research Institute US
• Hebron University PS
• Columbia University US
• Merck & Co., Inc., Rahway, NJ, USA (United States) US
• Dana-Farber Cancer Institute US
• Vanderbilt University US
• The University of Sydney AU
• Westmead Hospital AU
• University of Pennsylvania US
• Cornell University US
• University of California, San Francisco US
• Institut Català d'Oncologia ES
• Memorial Sloan Kettering Cancer Center US
• Princess Margaret Cancer Centre CA
• Samsung Medical Center KR

Related Publications